Stock Analysis, Dividends, Split History

GNMX / Aevi Genomic Medicine, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.16
Volume103,100.00
Market Cap ($M)66.46
Enterprise Value ($M)47.31
Book Value ($M)15.29
Book Value / Share0.26
Price / Book4.35
NCAV ($M)15.06
NCAV / Share0.25
Price / NCAV4.57
Share Statistics
Common Stock Shares Outstanding 59,332,265
Common Shares Outstanding 59,337,265
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.13
Return on Assets (ROA)-0.86
Return on Equity (ROE)-0.99
Balance Sheet (mrq) ($M)
Assets20.23
Liabilities4.94
Quick Ration/a
Current Ratio4.05
Income Statement (mra) ($M)
Operating Income-34.70
Net Income-34.71
Earnings Per Share Basic-0.83
Earnings Per Share Diluted-0.83
Cash Flow Statement (mra) ($M)
Cash From Operations-33.25
Cash from Investing0.15
Cash from Financing0.15
Identifiers and Descriptors
CUSIP58436Q203
Central Index Key (CIK)1138776
Related CUSIPS
00835P905 00835P955

Split History

Stock splits are used by Aevi Genomic Medicine, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
GNMX: Aevi Genomic Medicine Analysis and Research Report

2018-05-14 - Asif

Overview Aevi Genomic is a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. The company look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. Aevi Genomic has partnered with the Center for Applied Genomics, or CAG, at The Children’s Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug developm...

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Evaluating KemPharm's KP415, Part 2: The History Of ADHD Treatment And The Competitive Landscape

2018-06-21 seekingalpha
KemPharm will soon publish the results of its Phase 3 clinical trial for KP415, a prodrug of dexmethylphenidate. (73-2)

Aevi Genomic Medicine: Try Subgroups Until It Works?

2018-05-20 seekingalpha
Aevi's current strategy has a reasonable chance of success, but the stock has several red flags and remains highly speculative. (20-0)

Aevi Genomic (GNMX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

2018-03-29 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this event. (16-1)

Aevi Genomic Medicine, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-03-14 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with their 2017 Q4 earnings call. (16-0)

Aevi Genomic Medicine's (GNMX) CEO Mike Cola on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Q4 2017 Earnings Conference Call March 13, 2018 8:30 AM ET (16-0)

CUSIP: 58436Q203